morphine-3-glucuronide and Kidney-Diseases

morphine-3-glucuronide has been researched along with Kidney-Diseases* in 2 studies

Reviews

2 review(s) available for morphine-3-glucuronide and Kidney-Diseases

ArticleYear
Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
    Current clinical pharmacology, 2006, Volume: 1, Issue:1

    This article reviews the pharmacokinetics of heroin after intravenous, oral, intranasal, intramuscular and rectal application and after inhalation in humans, with a special focus on heroin maintenance therapy in heroin dependent patients. In heroin maintenance therapy high doses pharmaceutically prepared heroin (up to 1000 mg/day) are prescribed to chronic heroin dependents, who do not respond to conventional interventions such as methadone maintenance treatment. Possible drug-drug interactions with the hydrolysis of heroin into 6-monoacetylmorphine and morphine, the glucuronidation of morphine and interactions with drug transporting proteins are described. Since renal and hepatic impairment is common in the special population of heroin dependent patients, specific attention was paid on the impact of renal and hepatic impairment. Hepatic impairment did not seem to have a clinically relevant effect on the pharmacokinetics of heroin and its metabolites. However, some modest effects of renal impairment have been noted, and therefore control of the creatinine clearance during heroin-assisted treatment seems recommendable.

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Interactions; Heroin; Humans; Kidney Diseases; Liver Diseases; Morphine; Morphine Derivatives

2006
Systematic review of factors affecting the ratios of morphine and its major metabolites.
    Pain, 1998, Volume: 74, Issue:1

    In a systematic review of 57 studies with information on 1232 patients we examined the effect of age, renal impairment, route of administration, and method of analysis on the ratios of morphine-3-glucuronide:morphine (M3G:M) and morphine-6-glucuronide:morphine (M6G:M) and the relative concentrations of M3G and M6G. Across all studies the range of the ratios of metabolites to morphine was wide (0.001-504 for M3G:M, and 0-97 for M6G:M). Neonates produced morphine glucuronides at a lower rate than older children or adults. Metabolite ratios were higher in renal impairment. Routes of administration which avoided first pass metabolism (intravenous, transdermal, rectal, intramuscular, epidural and intrathecal) resulted in lower metabolite production than oral, buccal or sublingual. Metabolite production was similar for single and multiple dosing. There was no evidence of differences between methods of assay. There was a high correlation between the two glucuronide metabolites in spite of the different situations studied, supporting a single glucuronidating enzyme. Morphine was present in CSF at a fourfold higher concentration than the glucuronide metabolites.

    Topics: Adult; Aging; Analgesics, Opioid; Child; Dose-Response Relationship, Drug; Drug Administration Routes; Humans; Infant, Newborn; Kidney Diseases; Morphine; Morphine Derivatives

1998